肥胖与内脏脂肪是否促进射血分数降低的心力衰竭?
本文综述肥胖及内脏脂肪在射血分数保留的心力衰竭(HFpEF)与射血分数降低的心力衰竭(HFrEF)中的不同作用。肥胖是HFpEF的核心致病因素,但大规模试验及社区研究显示其并不预测HFrEF发生,心外膜脂肪在HFrEF中反而减少且预后不良。肥胖相关生物标志物及治疗反应在两类心衰中亦存在差异,提示肥胖对HFrEF的作用尚不明确。
要点
- 肥胖与中心性脂肪是HFpEF的重要致病因素,但不预测HFrEF发生。
- 心外膜脂肪在HFpEF中增加,在HFrEF中减少且减少提示预后不良。
- 中心性肥胖可识别对盐皮质激素受体拮抗剂反应更好的心衰患者。
核心结论
- 肥胖与内脏脂肪在HFpEF发病中起重要作用,但其在HFrEF发生和进展中的作用尚不明确。
研究设计与样本
- 本文为综述,总结大规模临床试验及社区研究中肥胖与心衰关系的证据。
主要发现
- 在无心脏病的社区人群中,肥胖或中心性脂肪可预测HFpEF发生,但不预测HFrEF。
- 心外膜脂肪在HFpEF中增加,在HFrEF中减少,且减少具有不良预后意义。
- 腰高比升高与HFpEF不良结局的关联强于HFrEF。
- 社区中hsCRP升高预示HFpEF发生,但不预示HFrEF。
- 肥胖是HFpEF中瘦素和脂联素水平的主要决定因素,而HFrEF中可能由心脏和神经激素信号驱动。
关键数值与推荐
- 中心性肥胖可识别对盐皮质激素受体拮抗剂反应更好的HFpEF和HFrEF患者。
- 中心性肥胖可识别对脑啡肽酶抑制或SGLT2抑制剂反应更好的HFpEF患者,但HFrEF患者无此特点。
- 基于肠促胰岛素的药物减重可降低HFpEF患者收缩压并减少心衰恶化事件风险,但HFrEF患者无类似获益。
临床怎么用
- 临床中应区分心衰类型评估肥胖相关风险,HFpEF患者需关注中心性肥胖及炎症标志物。
- 中心性肥胖有助于筛选可能从盐皮质激素受体拮抗剂、脑啡肽酶抑制或SGLT2抑制剂中获益的HFpEF患者。
- HFrEF患者减重及肥胖干预的获益尚不明确,需个体化评估。
局限性
- 本文为综述,未提供原始研究数据,结论基于现有文献总结。
- 肥胖与HFrEF因果关系的证据有限,需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Obesity or excess visceral adiposity plays a fundamental role in the pathogenesis of heart failure with preserved ejection fraction (HFpEF), but it is not clear that an expanded adipose tissue mass contributes importantly to the evolution and progression of heart failure with reduced ejection fraction (HFrEF). Whereas central adiposity characterizes most patients with HFpEF, obesity was not a remarkable feature of HFrEF in the large-scale trials carried out in the 1980s and 1990s, and studies typically characterized obesity as a protective factor against adverse outcomes. In the general community without apparent heart disease, the finding of obesity or central adiposity precedes and predicts the subsequent occurrence of HFpEF, but not HFrEF. The mass of epicardial adipose tissue-an important source of cardioactive molecules-is expanded in HFpEF, but it is diminished in HFrEF, and the decrease has adverse prognostic significance. An increased waist-to-height ratio (a marker of excess abdominal adiposity) is more strongly associated with adverse heart failure outcomes in HFpEF than in HFrEF. Systemic inflammation [as reflected by elevations of high-sensitivity C-reactive protein (hsCRP)] in the general community presages the development of HFpEF, but not HFrEF, presumably because excess adiposity augments hsCRP in HFpEF, whereas increases in hsCRP in HFrEF may be related to coexisting atherosclerosis or clinical congestion. Whereas obesity is the principal determinant of serum levels of leptin and adiponectin in HFpEF, cardiac and neurohormonal signalling may drive circulating levels of these adipokines in HFrEF. Central obesity identifies patients more likely to respond to mineralocorticoid receptor antagonists in both HFpEF and in HFrEF, but this feature also identifies patients more likely to respond neprilysin inhibition or sodium-glucose cotransporter 2 inhibitors if they have HFpEF, but not HFrEF. Weight loss by incretin-based drugs lowers systolic blood pressure in patients with HFpEF, but potentially not with HFrEF, and such weight loss is accompanied by a reduced risk of worsening heart failure events in patients with HFpEF, but without a similar benefit in HFrEF. Taken collectively, these observations raise important questions about the potential role of obesity and visceral adiposity as contributing factors in the evolution and progression of HFrEF.
引用
- Packer M. Do obesity and visceral adiposity promote heart failure with reduced ejection fraction? Eur Heart J. 2026. PMID: 40891153. doi:10.1093/eurheartj/ehaf645
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。